Vetter a winner of the Fraunhofer Clean Manufacturing Award CLEAN! 2018
![](/46/pdcnewsitem/07/15/53/image_large.jpg)
Dr.-Ing. Udo Gommel (left), Head of Department Fraunhofer IPA hands over the clean manufacturing award CLEAN! 2018 to Dr. Ute Schleyer, Project Manager Plant and Site Development at Vetter.
Vetter innovations in aseptic production increases the competitiveness of its customers.
Vetter is one of the winners of the clean manufacturing award CLEAN! 2018. The pharmaceutical service provider was able to convince the independent expert jury of the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) with its innovative Vetter CleanRoom Technology V-CRT. The prize was awarded as part of the LOUNGES 2018, an associated trade event in the clean manufacturing sector.
With the CLEAN! award, the Fraunhofer IPA honors groundbreaking developments in clean technology. "The production of active pharmaceutical ingredients, microchips or nanoproducts would be unthinkable without a high-purity manufacturing environment," says Dr.-Ing. Udo Gommel, Head of Department Fraunhofer IPA. "Vetter drives innovations in aseptic production and thereby increases the competitiveness of its customers. This achievement is honored by the Fraunhofer clean manufacturing award CLEAN! 2018." Important award and evaluation criteria included innovation leap, sustainability and industrial feasibility of the application concept. The Fraunhofer IPA is an institution of the Fraunhofer-Gesellschaft, Munich, that promotes applied research. It is particularly concerned with the development of sustainable and pioneering products.
Bernd Stauss, Senior Vice President Production/Engineering at Vetter, says: "We continue to develop our technologies to meet the complex and ever-increasing demands for quality and flexibility in pharmaceutical manufacturing. We are very pleased that this has now been honored with the Fraunhofer clean manufacturing award CLEAN! 2018 for our cleanroom concept V-CRT."
V-CRT is a holistic manufacturing technology developed by Vetter for the safe aseptic filling of injection systems. The innovative approach combines the advantages of isolators with Restricted Access Barrier Systems (RABS) and is based on the idea of fully automated decontamination of the entire cleanroom with hydrogen peroxide (H2O2). The result is the highest possible safety in the prevention of contamination as well as a flexible production process. Following the successful commercial implementation and validation of V-CRT in 2017, the technology will be used in all cleanrooms at Vetter by 2025.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance